Core Viewpoint - The company acknowledges the long-term potential of the medical robotics market but indicates that large-scale commercialization will take time [1] Group 1: Product Development and Market Application - The company has developed exoskeleton robots, including medical and portable versions, with the portable version currently being trialed in some scenic areas, receiving positive feedback [1] - The company is also focusing on brain-controlled exoskeleton products and companion robots, having the technical reserves to quickly advance productization when market opportunities mature [1]

一、网上申购情况及网上发行初步中签率 根据上交所提供的数据，本次网上发行有效申购户数为5,205,789户，有效 申购股数为41,908,239,000 股，网上发行初步中签率约为0.02176183%。配号总 数为83,816,478个，号码范围为100,000,000,000- 100,083,816,477。 一、网上申购情况及网上发行初步中签率 根据上交所提供的数据，本次网上发行有效申购户数为5,205,789户，有效 申购股数为41,908,239,000 股，网上发行初步中签率约为0.02176183%。配号总 数为83,816,478个，号码范围为100,000,000,000- 100,083,816,477。 二、回拨机制实施、发行结构及网上发行最终中签率 根据《深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市发 行安排及初步询价公 告》、《深圳北芯生命科技股份有限公司首次公开发行股票并 在科创板上市发行公告》公布的回拨机 制，由于本次网上发行初步有效申购倍数 为4,595.20 倍，超过 100倍，发行人和保荐人（主承销商）决 定启动回拨机制， 对网下、网上发行的规模进行调节，将 ...

Group 1: Nipah Virus Overview - The Nipah virus, with a mortality rate ranging from 40% to 75%, has re-emerged in West Bengal, India, raising international concern [1][2] - Recent reports indicate five cases of Nipah virus infection in West Bengal, including healthcare workers, leading to nearly 100 individuals being quarantined [2] - Since 2001, India has experienced multiple outbreaks of the Nipah virus, with a total of 754 confirmed cases and 435 deaths across five countries, including India and Bangladesh, as of May 2024 [3] Group 2: Health Monitoring and Response - Thailand and Nepal have intensified health monitoring and quarantine measures for travelers from India, while China has included Nipah virus in its entry monitoring protocols [4] - The Chinese Academy of Sciences has announced the discovery of an oral antiviral drug, VV116, which shows significant efficacy against the Nipah virus in animal studies [5][6] Group 3: Diagnostic and Testing Developments - Several Chinese companies have developed and disclosed testing kits for the Nipah virus, including PCR nucleic acid test kits with high sensitivity [10][11] - Companies like ZhiJiang Biology and Shuoshi Biology have provided testing kits to customs and disease control agencies to aid in monitoring and prevention efforts [10][11] Group 4: Market Reactions - Following the news of the Nipah virus outbreak, the A-share market saw a surge in the vaccine and in vitro diagnostic (IVD) sectors, with many stocks hitting the daily limit up, although there was a significant pullback the following day [12]

机构：西部证券 研究员：陆伏崴/吕晔 公司与威高血净达成子公司威高普瑞的交易协议。威高血净将收购公司非全资附属公司威高普瑞100% 的股权；作为交易对价，威高血净将向各威高普瑞股东发行相应数量的对价股份。交易标的资产即威高 普瑞的最终对价为85.11 亿元人民币，所对应的2024 年静态PE 倍数为14.66 倍，最终对价股份数目为 2.72 亿股，占威高血净当前已发行总股数的65.11%，经扩大发行总股数的39.43%。截至2026 年1 月5 日，公司持有威高血净23.53%的股权。交易完成后，威高普瑞将成为威高血净的全资附属公司；公司 持有威高血净52.10%的股份，威高血净及其附属公司的账目将并入公司的财务报表。 投资建议：不考虑血净并表影像，我们预计2025-2027 年公司将实现归母净利润20.91/22.87/25.07 亿 元，同比变化1.18%/9.37%/9.62%，首次覆盖，给予"增持"评级。 风险提示：经销商管理和维护风险、部分原材料主要向境外采购的风险、技术研发风险、产品发生质量 事故或不良事件的风险、行业政策变动的风险、市场竞争加剧的风险、地缘政治的带来的不确定风险等 生物制药行业 ...

Group 1 - Chengdu is enhancing its duty-free shopping experience by increasing the variety of products available in duty-free stores, aiming to promote local brands and products internationally [3][5] - As of November 30, 2025, Chengdu has over 600 duty-free stores, with more than 180 offering an "immediate purchase and refund" service, which has been optimized to include multiple refund methods [3][4] - The Chengdu Business Bureau is actively analyzing consumer preferences among international tourists to better tailor product offerings in duty-free stores, focusing on local cultural products and high-tech items [4][6] Group 2 - Local companies, such as Qianli Beiyikang Medical Technology Co., are keen to enter duty-free stores to enhance brand visibility and access high-value consumer segments, with products already reaching 70 countries [5][6] - The strategy of including more local products in duty-free stores is expected to improve the shopping experience for tourists and increase inbound consumption [5][6] - The competitive edge of domestic products is being validated through sales data, with popular categories including clothing, bags, and electronics, indicating a strong market for culturally significant items [6]

Group 1 - The core viewpoint of the news is that Aojing Medical has seen a stock price increase of 5.15%, reaching 24.50 yuan per share, with a trading volume of 1.11 billion yuan and a turnover rate of 3.44%, resulting in a total market capitalization of 33.57 billion yuan [1] - Aojing Medical, established on December 22, 2004, and listed on May 21, 2021, focuses on the research, production, and sales of high-end biomedical materials and related medical devices [1] - The main revenue composition of Aojing Medical includes: 骼金 74.91%, 颅瑞 16.35%, 齿贝 4.15%, 口腔种植体 2.70%, and other products 1.87% [1] Group 2 - From the perspective of Aojing Medical's top ten circulating shareholders, a fund under Rongtong Fund has entered the top ten shareholders, holding 2.4 million shares, which accounts for 1.75% of the circulating shares [2] - The Rongtong Health Industry Flexible Allocation Mixed A/B fund (000727) has achieved a year-to-date return of 11.06%, ranking 1397 out of 8861 in its category, and a one-year return of 29.24%, ranking 4302 out of 8126 [2] - The fund manager of Rongtong Health Industry Flexible Allocation Mixed A/B is Wan Minyuan, who has a total fund asset scale of 4.763 billion yuan and has achieved a best fund return of 151.58% during his tenure [3]

今日早盘，科创板系列指数下探后集体反弹，截至午间收盘，科创成长指数上涨1.5%，科创100指数上涨1.3%，科创50指数上涨0.6%，科创200指数、科创 综指均上涨0.4%。 科创板系列指数基本情况跟踪 (2026年1月27日) 科创50ETF易方达 低费率 1.3% 220. 8倍 跟踪上证科创板50成份指数 该指数由科创板中市值大、流动性 好的50只股票组成,"硬科技"龙 头特征显著,半导体占比超65%, 与医疗器械、软件开发、光伏设备 行业合计占比近80% 截至午间收盘 该指数涨跌 该指数 滚动市盈率 科创100ETF易方达 保其2 跟踪上证科创板100指数 该指数由科创板中市值中等且流动 性较好的100只股票组成,聚焦中 小科创企业,电子、电力设备、医 药生物、计算机行业合计占比超 75%,其中电子、电力设备行业占 比较高 截至午间收盘 该指数涨跌 该指数 滚动市盈率 科创200ETF易方达 FF = 跟踪上证科创板200指数 该指数由科创板中市值偏小、流动 性较好的200只股票组成,聚焦小 市值"成长潜力"科创企业,电子、 医药牛物、机械设备行业合计占比 截至午间收盘 该指数涨跌 该指数 滚动币盈 ...

Core Viewpoint - The article highlights the outbreak of Nipah virus in West Bengal, India, and emphasizes the critical role of rapid and accurate testing in epidemic prevention and monitoring, given the virus's high mortality rate of 40%-75% and the absence of effective vaccines or treatments [3]. Group 1: Industry Response - Companies such as Capbio, Shuoshi Bio, and Zhongke Shengyi have quickly responded to the Nipah virus outbreak by providing testing kits to aid in epidemic monitoring and prevention [4]. - The Nipah virus is classified as a newly emerging zoonotic virus, causing severe diseases characterized by encephalitis or respiratory illnesses in infected individuals [6]. Group 2: Product Offerings - Capbio offers a range of Nipah virus nucleic acid testing kits using fluorescence PCR methods, with various packaging options available [11]. - The testing kits include specifications for different sample types such as serum, plasma, throat swabs, whole blood, urine, and viral cultures, with a detection limit of 500 copies/mL and a report time of 70 minutes [18].

证券日报网讯1月26日，迈瑞医疗（300760）在互动平台回答投资者提问时表示，当今数字化转型已成 为企业发展的核心驱动力。借助数字力量，迈瑞的业务链管理从供应商端至客户端，各环节均实现了协 同合作，更好地保障了产品生产、交付、服务的质量，为迈瑞医疗在全球市场的稳健发展筑牢根基。通 过数字化建设，公司实现了供应链业务全链路运营支撑，可更好地支持经营分析、现金流管理、运营结 果分析、预算管理、以及合规与风险管理流程的运转。公司的供应链驾驶舱整合了各个环节的数据，打 破信息孤岛，确保产品从物料供应到交付的每一环节都符合法规和质量要求。2024年，公司重点强化了 总部与各生产基地的数字化建设、以及海外工厂和仓库的系统对接。针对国内生产基地，新建砀山生产 基地实现了数字供应链系统基础生产业务的全覆盖，并完成了与南京生产基地的系统联通，实现多基地 的生产协同。武汉生产基地数字化系统也已完成并投入运行，支持高值医用耗材业务。在海外，公司启 动了欧洲生产基地数字化系统的本土化建设，打通了国内仓储与欧洲外仓系统，实现高效对接，强化了 区域成品交付能力。凭借坚实的信息化基础，公司继续扩大信息化系统覆盖的范围和深度，建设数字化 ...

Core Viewpoint - The company, Dabo Medical, anticipates a significant increase in net profit for the fiscal year 2025, projecting a range of approximately 580 million to 610 million yuan, representing a year-on-year growth of about 62.55% to 70.96% compared to 357 million yuan in the previous year [1] Financial Performance - The expected basic earnings per share for 2025 are projected to be between 1.43 yuan and 1.5 yuan, which shows a notable increase from 0.86 yuan per share in the same period last year [1] Growth Drivers - The company attributes its performance growth to a focus on its core business, commitment to product innovation, technical services, and international development strategies, which have driven the continuous and stable development of its various business segments [1]